TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22422593

Group type: EXPERIMENTAL
Intervention: Microfracture (MF)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Osteochondral autograft transplantation (OAT)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Autologous chondrocyte implantation (ACI)
Number of subjects: 70
Study: 20946444

Group type: EXPERIMENTAL
Intervention: Structured discharge education
Number of subjects: 59

Group type: COMPARATOR
Intervention: Traditional discharge education (Control)
Number of subjects: 59
Study: 17332026

Group type: EXPERIMENTAL
Intervention: Serial electrical cardioversion (ECV) and serial antiarrhythmic drug strategy in patients with systolic heart failure
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (patients without heart failure)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Serial ECV and antiarrhythmic drug approach in patients with systolic heart failure
Number of subjects: 64
Study: 15810945

Group type: EXPERIMENTAL
Intervention: Cranberry juice (n = 97)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Placebo (n = 92)
Number of subjects: 189
Study: 12378376

Group type: EXPERIMENTAL
Intervention: Treatment for hypertension
Number of subjects: 1866

Group type: EXPERIMENTAL
Intervention: Treatment for hypertension in microalbuminuric patients
Number of subjects: 1866

Group type: EXPERIMENTAL
Intervention: Treatment for hypertension in macroalbuminuric patients
Number of subjects: 1866

Group type: EXPERIMENTAL
Intervention: Use of more than one anti-hypertensive drug
Number of subjects: 1866

Group type: EXPERIMENTAL
Intervention: Use of ACE inhibitors
Number of subjects: 1866
Study: 9473754

Group type: EXPERIMENTAL
Intervention: VACA (vincristine/actinomycin D/cyclophosphamide/adriamycin)
Number of subjects: 61

Group type: COMPARATOR
Intervention: VACAD (VACA plus imidazole carboxamide (DTIC))
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Group III disease (regional unresected)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Grade 1 and 2 histology
Number of subjects: 61
Study: 8568022

Group type: EXPERIMENTAL
Intervention: Partner-support, incentive-based educational program
Number of subjects: 68

Group type: COMPARATOR
Intervention: Usual breast feeding (control)
Number of subjects: 68
Study: 2245548

Group type: EXPERIMENTAL
Intervention: Intraoperative irrigation of long‐acting dexamethasone before incision closure
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standard operative procedure (control group)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Steroid group
Number of subjects: 45
Study: 221812

Group type: EXPERIMENTAL
Intervention: Human leukocyte interferon (7 x 10(4) U/kg/day for 5 days)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Human leukocyte interferon
Number of subjects: 37
Study: 31754239

Group type: EXPERIMENTAL
Intervention: Genetically increased serum uric acid
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Waist circumference
Number of subjects: 10000
Study: 30699287

Group type: EXPERIMENTAL
Intervention: Target enrichment method for identifying non-reference L1Hs
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Target enrichment method
Number of subjects: 1
Study: 28353056

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg oral psilocybin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.45 mg/kg oral psilocybin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg oral psilocybin
Number of subjects: 12
Study: 25496000

Group type: EXPERIMENTAL
Intervention: Fractionated microneedle radiofrequency (FMR)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 25
Study: 23407049

Group type: EXPERIMENTAL
Intervention: First-line monotherapy capecitabine
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Capecitabine-irinotecan combination therapy
Number of subjects: 268

Group type: COMPARATOR
Intervention: MTHFR 1298A>C and 677C>T genotypes
Number of subjects: 268
Study: 21971929

Group type: EXPERIMENTAL
Intervention: Image-enhanced colonoscopy (HD-NBI)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Standard definition white light colonoscopy (SDWL)
Number of subjects: 96
Study: 19820812

Group type: EXPERIMENTAL
Intervention: Expiratory flow increase technique (EFIT)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Vibration accompanied by postural drainage (PD)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 81
Study: 16735941

Group type: EXPERIMENTAL
Intervention: EA 1.8 mg/day
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: EA 0.9 mg/day
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: EA 0.45 mg/day
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: EA 0.9 mg/day and EA 1.8 mg/day
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: All EA groups
Number of subjects: 552

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 552
Study: 15316247

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 11210885

Group type: EXPERIMENTAL
Intervention: Pneumatic artificial source of voice incorporated in a regular tracheoesophageal (TE) shunt valve
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pneumatic artificial source of voice
Number of subjects: 6
Study: 9149451

Group type: EXPERIMENTAL
Intervention: Combined condition
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Influence condition
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Negative Consequences condition
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 77
Study: 8425345

Group type: EXPERIMENTAL
Intervention: Active pulsed electromagnetic fields (PEMFs) treatment
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control (placebo) treatment
Number of subjects: 37
Study: 3315579

Group type: EXPERIMENTAL
Intervention: APSAC 15U
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: APSAC 20U
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: APSAC 25U
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: APSAC 30U
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 30861537

Group type: EXPERIMENTAL
Intervention: Allograft bone chips mixed with autologous bone marrow (BM) in 19 patients (group A)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Allograft bone chips only in 17 patients (group B)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Allograft bone chips mixed with autologous BM in group A
Number of subjects: 36

Group type: COMPARATOR
Intervention: Allograft bone chips only in group B
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 36
Study: 30239290

Group type: EXPERIMENTAL
Intervention: Postexercise BFR (30% RP)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: BFR during exercise (30% RD)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Heavy REx (75% 1RM)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Traditional low-load BFR REx (30%)
Number of subjects: 10
Study: 26813845

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for insomnia (CBTi)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 31
Study: 24218307

Group type: EXPERIMENTAL
Intervention: Water exchange
Number of subjects: 672

Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 672
Study: 22067982

Group type: EXPERIMENTAL
Intervention: Noninvasive positive pressure ventilation plus standard of care
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 20
Study: 20377796

Group type: EXPERIMENTAL
Intervention: Potentiality education program
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 59
Study: 18992162

Group type: EXPERIMENTAL
Intervention: Carboplatin (one cycle)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiation Therapy (RT)
Number of subjects: 0
Study: 16531163

Group type: EXPERIMENTAL
Intervention: ethinylestradiol 15 mug/gestodene 60 mug (EE/GST)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: ethinylestradiol 30 mug/drospirenone 3 mg (EE/DRS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: male condom (control group)
Number of subjects: 80
Study: 14584297

Group type: EXPERIMENTAL
Intervention: Thiazide or indapamide treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Potassium citrate (without sodium)
Number of subjects: 0
Study: 10950230

Group type: EXPERIMENTAL
Intervention: Bug-busting (wet combing with a fine-toothed comb) every 3-4 days for 2 weeks
Number of subjects: 72

Group type: COMPARATOR
Intervention: Malathion lotion (0.5%) applied twice, 7 days apart
Number of subjects: 72
Study: 8825255

Group type: EXPERIMENTAL
Intervention: Integrated service agencies (ISAs) with financing reform and assertive continuous treatment team approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Integrated service agencies (ISAs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison groups receiving usual services
Number of subjects: 0
Study: 1563207

Group type: EXPERIMENTAL
Intervention: Bidisomide (SC-40230) intravenous doses ranging from 0.03 to 2.5 mg/kg
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Bidisomide (SC-40230) 2.0 mg/kg orally and intravenously
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 6362417

Group type: EXPERIMENTAL
Intervention: Extraperitoneal cesarean section plus prophylactic antibiotics (group C)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Transperitoneal primary cesarean section (control group)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Extraperitoneal cesarean section (group A)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Extraperitoneal cesarean section (group B)
Number of subjects: 91
Study: 31066956

Group type: EXPERIMENTAL
Intervention: Urethral bulking therapy
Number of subjects: 0
Study: 29629400

Group type: EXPERIMENTAL
Intervention: Aclidinium bromide 400 µg twice daily
Number of subjects: 0
Study: 26974022

Group type: EXPERIMENTAL
Intervention: IT hydromorphone at ED90 of 75 μg
Number of subjects: 80

Group type: COMPARATOR
Intervention: IT morphine at ED90 of 150 μg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: IT hydromorphone (ED90 or higher)
Number of subjects: 80

Group type: COMPARATOR
Intervention: IT morphine (ED90 or higher)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: IT hydromorphone and IT morphine
Number of subjects: 80
Study: 24611935

Group type: EXPERIMENTAL
Intervention: CHO+PRO
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CHO+PROh
Number of subjects: 60

Group type: COMPARATOR
Intervention: CHO
Number of subjects: 60
Study: 22964561

Group type: EXPERIMENTAL
Intervention: Dialectical Behaviour Therapy (DBT) for 12 months
Number of subjects: 80

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: DBT (completed treatment)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: DBT (non-completers)
Number of subjects: 80
Study: 20406655

Group type: EXPERIMENTAL
Intervention: US obesity prevention intervention
Number of subjects: 506

Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 506
Study: 17928325

Group type: EXPERIMENTAL
Intervention: Albendazole 15 mg/kg/day for 2 weeks
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (no cysticidal therapy)
Number of subjects: 43
Study: 15994046

Group type: EXPERIMENTAL
Intervention: Ultrasonography (US)
Number of subjects: 89
Study: 12477681

Group type: EXPERIMENTAL
Intervention: Fentanyl infusion at a rate of 0.75, 1.0, or 1.5 microg x kg(‐1) x min(‐1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Remifentanil infusion at a rate of 0.75, 1.0, or 1.5 microg x kg(‐1) x min(‐1)
Number of subjects: 60
Study: 10614716

Group type: EXPERIMENTAL
Intervention: IFN alpha therapy
Number of subjects: 18
Study: 8556997

Group type: EXPERIMENTAL
Intervention: Vecuronium as a priming agent
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rocuronium as a priming agent
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rocuronium and vecuronium as priming agents
Number of subjects: 0
Study: 1930849

Group type: EXPERIMENTAL
Intervention: 15 mmol Mg added to a free diet for 6 months
Number of subjects: 71
Study: 6284661

Group type: EXPERIMENTAL
Intervention: Diltiazem 240 mg/day
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Diltiazem (various doses)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31478919

Group type: EXPERIMENTAL
Intervention: Social contact person engaged by phone (intervention)
Number of subjects: 399

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 399
Study: 30135389

Group type: EXPERIMENTAL
Intervention: High walkability areas
Number of subjects: 731

Group type: COMPARATOR
Intervention: Low walkability areas
Number of subjects: 731

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 731

Group type: EXPERIMENTAL
Intervention: Urban and suburban areas
Number of subjects: 731

Group type: COMPARATOR
Intervention: Rural area
Number of subjects: 731
Study: 26727718

Group type: EXPERIMENTAL
Intervention: Information on overdiagnosis
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: Prior awareness of overdiagnosis
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: Higher education level and Medical Aid Program
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: Stronger beliefs on efficacy of cancer screening
Number of subjects: 586
Study: 24203062

Group type: EXPERIMENTAL
Intervention: 17β‐estradiol (E2)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 17β‐estradiol (E2) with GHRH
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo with GHRH
Number of subjects: 24
Study: 22331756

Group type: EXPERIMENTAL
Intervention: Cefdinir granule (test) 100 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cefdinir capsule (reference) 100 mg
Number of subjects: 20
Study: 19700248

Group type: EXPERIMENTAL
Intervention: Accelerated partial breast irradiation plus intensity‐modulated radiotherapy (Arm B)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Conventional (tangential field) fractionated whole breast treatment (Arm A)
Number of subjects: 259
Study: 17427522

Group type: EXPERIMENTAL
Intervention: VCD (video compact disc) demonstrating nasogastric intubation
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (no VCD)
Number of subjects: 61
Study: 15378675

Group type: EXPERIMENTAL
Intervention: Cortisol (0.5 mg/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cortisol (0.2 mg/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cocaine (0.2 mg/kg)
Number of subjects: 12
Study: 11473079

Group type: EXPERIMENTAL
Intervention: GLP-1 4 ng.kg(‐1).min(‐1) for 16 h/day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: GLP-1 4 ng.kg(‐1).min(‐1) for 24 h/day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: GLP-1 8 ng.kg(‐1).min(‐1) for 16 h/day
Number of subjects: 40
Study: 9869503

Group type: EXPERIMENTAL
Intervention: Tedisamil dihydrochloride administered intravenously
Number of subjects: 9
Study: 7759146

Group type: EXPERIMENTAL
Intervention: BioLogic-DT sorbent suspension dialyser
Number of subjects: 10
Study: 2856651

Group type: EXPERIMENTAL
Intervention: Intravenous human growth hormone releasing factor (hGRF) (1 microgram/kg in 5 cc of normal saline infused over five minutes)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intravenous human growth hormone releasing factor (hGRF)
Number of subjects: 16
Study: 30965599

Group type: EXPERIMENTAL
Intervention: BoNT‐A combined with a four‐week ankle isokinetic treatment (n = 12)
Number of subjects: 25

Group type: COMPARATOR
Intervention: BoNT‐A alone (n = 13)
Number of subjects: 25
Study: 29194392

Group type: EXPERIMENTAL
Intervention: Menu-plus intervention (marketing campaign, employee trainings, promotional materials)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Menu-only intervention (new healthy child menu items)
Number of subjects: 8
Study: 26176357

Group type: EXPERIMENTAL
Intervention: Video distraction (group V)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Parental presence (group P)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Combination of video distraction plus parental presence (group VP)
Number of subjects: 117
Study: 23405022

Group type: EXPERIMENTAL
Intervention: Plantar perceptual learning task (hardness discrimination training)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (same task without hardness discrimination)
Number of subjects: 86
Study: 21296780

Group type: EXPERIMENTAL
Intervention: Candesartan-based regimen (n=257)
Number of subjects: 512

Group type: COMPARATOR
Intervention: Imidapril-based regimen (n=255)
Number of subjects: 512
Study: 19447071

Group type: EXPERIMENTAL
Intervention: Standardised nursing wound care record
Number of subjects: 126
Study: 15337331

Group type: EXPERIMENTAL
Intervention: Vitamin B-12 treatment
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 10027509

Group type: EXPERIMENTAL
Intervention: Tryptophan (TRP) depletion
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Lysine (LYS) depletion
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 7743570

Group type: EXPERIMENTAL
Intervention: 5.0% isoflurane
Number of subjects: 30

Group type: COMPARATOR
Intervention: 2.5% isoflurane
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fentanyl 2 micrograms.kg‐1 i.v. with 5.0% isoflurane
Number of subjects: 30
Study: 2328112

Group type: EXPERIMENTAL
Intervention: Topical ciprofloxacin (3 drops, 250 micrograms/mL in saline solution) locally twice a day (group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combined treatment of topical ciprofloxacin and oral ciprofloxacin (group C)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral ciprofloxacin (250 mg orally twice a day) (group A)
Number of subjects: 60
Study: 6102409

Group type: EXPERIMENTAL
Intervention: Floctafenine 1.2 g daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Enteric-coated acetylsalicylic acid (ACSA) 2.6 g daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31381078

Group type: EXPERIMENTAL
Intervention: Early limited formula
Number of subjects: 0
Study: 28376768

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (1200 IU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26866417

Group type: EXPERIMENTAL
Intervention: Total knee replacement surgery
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Muscle strength
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Knee pain, activity limitations, number of comorbidities, lack of energy
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Female sex, number of comorbidities, depression, fatigue
Number of subjects: 422
Study: 23834253

Group type: EXPERIMENTAL
Intervention: Synthetic extracellular matrix protein as an adjunct to standard care
Number of subjects: 45
Study: 22818727

Group type: EXPERIMENTAL
Intervention: Experimental group (n=25) attended program sessions with nutrition information, hands-on cooking instruction, and prepared recipes.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (n=25) received mailed relevant handouts and recipes.
Number of subjects: 50
Study: 19030947

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type-A (BTX-A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 0
Study: 17635734

Group type: EXPERIMENTAL
Intervention: Combined anticoagulant and antiplatelet therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antiplatelet therapy alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anticoagulant therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin and clopidogrel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triple therapy
Number of subjects: 0
Study: 16034276

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 45

Group type: COMPARATOR
Intervention: Methylphenidate
Number of subjects: 45
Study: 12445486

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) infusion (30 microg/30 min)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (8 healthy subjects)
Number of subjects: 8
Study: 9435411

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rHGH) 0.2 mg/kg.day
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rHGH)
Number of subjects: 19
Study: 8085776

Group type: EXPERIMENTAL
Intervention: Diltiazem LP 300 mg (morning administration)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Diltiazem LP 300 mg (evening administration)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Diltiazem LP 300 mg (both morning and evening)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 2783183

Group type: EXPERIMENTAL
Intervention: KW-5805 (2.5 to 320 mg)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 30511840

Group type: EXPERIMENTAL
Intervention: Fish oil (n = 41, 4 capsules/day, equivalent to 2 g of eicosapentaenoic acid plus docosahexaenoic acid)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Flaxseed oil (n = 42, 4 capsules/day, equivalent to 2.5 g of α‐linolenic acid)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Corn oil (control group, n = 43)
Number of subjects: 126
Study: 28751544

Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation
Number of subjects: 750

Group type: COMPARATOR
Intervention: Radiofrequency catheter (RFC) ablation
Number of subjects: 750
Study: 26447153

Group type: EXPERIMENTAL
Intervention: 25(OH)D concentration ≥30 ng/mL
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: 25(OH)D concentration ≥30 ng/mL in former and current smokers
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: VDR FokI AA genotype
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: RXR rs7861779 TT genotype
Number of subjects: 209
Study: 23359034

Group type: EXPERIMENTAL
Intervention: Low-dose iterative reconstruction (LD-IR)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard-dose filtered back-projection (SD-FBP)
Number of subjects: 40